Human Vaccines-United States Market Status and Trend Report 2013-2023
Report Summary
Human Vaccines-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Human Vaccines industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Human Vaccines 2013-2017, and development forecast 2018-2023
Main market players of Human Vaccines in United States, with company and product introduction, position in the Human Vaccines market
Market status and development trend of Human Vaccines by types and applications
Cost and profit status of Human Vaccines, and marketing status
Market growth drivers and challenges
The report segments the United States Human Vaccines market as:
United States Human Vaccines Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Human Vaccines Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pneumococcal
Influenza
Hepatitis
HPV
Meningococcal
Rotavirus
Measles
Typhoid
Combination
United States Human Vaccines Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Pediatrics
Adolescents
Adults
Geriatrics
United States Human Vaccines Market: Players Segment Analysis (Company and Product introduction, Human Vaccines Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca
Bavarian Nordic
Bharat Biotech
CSL Limited
Emergent BioSolutions, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Mymetics
Novartis AG
Pfizer, Inc.
Sanofi
Shenzhen Kangtai Biological Products Co., Ltd.
Takeda Pharmaceutical Company Limited.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Human Vaccines-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Human Vaccines industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Human Vaccines 2013-2017, and development forecast 2018-2023
Main market players of Human Vaccines in United States, with company and product introduction, position in the Human Vaccines market
Market status and development trend of Human Vaccines by types and applications
Cost and profit status of Human Vaccines, and marketing status
Market growth drivers and challenges
The report segments the United States Human Vaccines market as:
United States Human Vaccines Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Human Vaccines Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pneumococcal
Influenza
Hepatitis
HPV
Meningococcal
Rotavirus
Measles
Typhoid
Combination
United States Human Vaccines Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Pediatrics
Adolescents
Adults
Geriatrics
United States Human Vaccines Market: Players Segment Analysis (Company and Product introduction, Human Vaccines Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca
Bavarian Nordic
Bharat Biotech
CSL Limited
Emergent BioSolutions, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Mymetics
Novartis AG
Pfizer, Inc.
Sanofi
Shenzhen Kangtai Biological Products Co., Ltd.
Takeda Pharmaceutical Company Limited.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF HUMAN VACCINES
1.1 Definition of Human Vaccines in This Report
1.2 Commercial Types of Human Vaccines
1.2.1 Pneumococcal
1.2.2 Influenza
1.2.3 Hepatitis
1.2.4 HPV
1.2.5 Meningococcal
1.2.6 Rotavirus
1.2.7 Measles
1.2.8 Typhoid
1.2.9 Combination
1.3 Downstream Application of Human Vaccines
1.3.1 Pediatrics
1.3.2 Adolescents
1.3.3 Adults
1.3.4 Geriatrics
1.4 Development History of Human Vaccines
1.5 Market Status and Trend of Human Vaccines 2013-2023
1.5.1 United States Human Vaccines Market Status and Trend 2013-2023
1.5.2 Regional Human Vaccines Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Human Vaccines in United States 2013-2017
2.2 Consumption Market of Human Vaccines in United States by Regions
2.2.1 Consumption Volume of Human Vaccines in United States by Regions
2.2.2 Revenue of Human Vaccines in United States by Regions
2.3 Market Analysis of Human Vaccines in United States by Regions
2.3.1 Market Analysis of Human Vaccines in New England 2013-2017
2.3.2 Market Analysis of Human Vaccines in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of Human Vaccines in The Midwest 2013-2017
2.3.4 Market Analysis of Human Vaccines in The West 2013-2017
2.3.5 Market Analysis of Human Vaccines in The South 2013-2017
2.3.6 Market Analysis of Human Vaccines in Southwest 2013-2017
2.4 Market Development Forecast of Human Vaccines in United States 2018-2023
2.4.1 Market Development Forecast of Human Vaccines in United States 2018-2023
2.4.2 Market Development Forecast of Human Vaccines by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of Human Vaccines in United States by Types
3.1.2 Revenue of Human Vaccines in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Human Vaccines in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Human Vaccines in United States by Downstream Industry
4.2 Demand Volume of Human Vaccines by Downstream Industry in Major Countries
4.2.1 Demand Volume of Human Vaccines by Downstream Industry in New England
4.2.2 Demand Volume of Human Vaccines by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of Human Vaccines by Downstream Industry in The Midwest
4.2.4 Demand Volume of Human Vaccines by Downstream Industry in The West
4.2.5 Demand Volume of Human Vaccines by Downstream Industry in The South
4.2.6 Demand Volume of Human Vaccines by Downstream Industry in Southwest
4.3 Market Forecast of Human Vaccines in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HUMAN VACCINES
5.1 United States Economy Situation and Trend Overview
5.2 Human Vaccines Downstream Industry Situation and Trend Overview
CHAPTER 6 HUMAN VACCINES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of Human Vaccines in United States by Major Players
6.2 Revenue of Human Vaccines in United States by Major Players
6.3 Basic Information of Human Vaccines by Major Players
6.3.1 Headquarters Location and Established Time of Human Vaccines Major Players
6.3.2 Employees and Revenue Level of Human Vaccines Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 HUMAN VACCINES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca
7.1.1 Company profile
7.1.2 Representative Human Vaccines Product
7.1.3 Human Vaccines Sales, Revenue, Price and Gross Margin of AstraZeneca
7.2 Bavarian Nordic
7.2.1 Company profile
7.2.2 Representative Human Vaccines Product
7.2.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bavarian Nordic
7.3 Bharat Biotech
7.3.1 Company profile
7.3.2 Representative Human Vaccines Product
7.3.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bharat Biotech
7.4 CSL Limited
7.4.1 Company profile
7.4.2 Representative Human Vaccines Product
7.4.3 Human Vaccines Sales, Revenue, Price and Gross Margin of CSL Limited
7.5 Emergent BioSolutions, Inc.
7.5.1 Company profile
7.5.2 Representative Human Vaccines Product
7.5.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Emergent BioSolutions, Inc.
7.6 GlaxoSmithKline plc
7.6.1 Company profile
7.6.2 Representative Human Vaccines Product
7.6.3 Human Vaccines Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.7 Johnson & Johnson
7.7.1 Company profile
7.7.2 Representative Human Vaccines Product
7.7.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.8 Merck & Co., Inc.
7.8.1 Company profile
7.8.2 Representative Human Vaccines Product
7.8.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.9 Mymetics
7.9.1 Company profile
7.9.2 Representative Human Vaccines Product
7.9.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Mymetics
7.10 Novartis AG
7.10.1 Company profile
7.10.2 Representative Human Vaccines Product
7.10.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Novartis AG
7.11 Pfizer, Inc.
7.11.1 Company profile
7.11.2 Representative Human Vaccines Product
7.11.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
7.12 Sanofi
7.12.1 Company profile
7.12.2 Representative Human Vaccines Product
7.12.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Sanofi
7.13 Shenzhen Kangtai Biological Products Co., Ltd.
7.13.1 Company profile
7.13.2 Representative Human Vaccines Product
7.13.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Shenzhen Kangtai Biological Products Co., Ltd.
7.14 Takeda Pharmaceutical Company Limited.
7.14.1 Company profile
7.14.2 Representative Human Vaccines Product
7.14.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HUMAN VACCINES
8.1 Industry Chain of Human Vaccines
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HUMAN VACCINES
9.1 Cost Structure Analysis of Human Vaccines
9.2 Raw Materials Cost Analysis of Human Vaccines
9.3 Labor Cost Analysis of Human Vaccines
9.4 Manufacturing Expenses Analysis of Human Vaccines
CHAPTER 10 MARKETING STATUS ANALYSIS OF HUMAN VACCINES
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Human Vaccines in This Report
1.2 Commercial Types of Human Vaccines
1.2.1 Pneumococcal
1.2.2 Influenza
1.2.3 Hepatitis
1.2.4 HPV
1.2.5 Meningococcal
1.2.6 Rotavirus
1.2.7 Measles
1.2.8 Typhoid
1.2.9 Combination
1.3 Downstream Application of Human Vaccines
1.3.1 Pediatrics
1.3.2 Adolescents
1.3.3 Adults
1.3.4 Geriatrics
1.4 Development History of Human Vaccines
1.5 Market Status and Trend of Human Vaccines 2013-2023
1.5.1 United States Human Vaccines Market Status and Trend 2013-2023
1.5.2 Regional Human Vaccines Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Human Vaccines in United States 2013-2017
2.2 Consumption Market of Human Vaccines in United States by Regions
2.2.1 Consumption Volume of Human Vaccines in United States by Regions
2.2.2 Revenue of Human Vaccines in United States by Regions
2.3 Market Analysis of Human Vaccines in United States by Regions
2.3.1 Market Analysis of Human Vaccines in New England 2013-2017
2.3.2 Market Analysis of Human Vaccines in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of Human Vaccines in The Midwest 2013-2017
2.3.4 Market Analysis of Human Vaccines in The West 2013-2017
2.3.5 Market Analysis of Human Vaccines in The South 2013-2017
2.3.6 Market Analysis of Human Vaccines in Southwest 2013-2017
2.4 Market Development Forecast of Human Vaccines in United States 2018-2023
2.4.1 Market Development Forecast of Human Vaccines in United States 2018-2023
2.4.2 Market Development Forecast of Human Vaccines by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of Human Vaccines in United States by Types
3.1.2 Revenue of Human Vaccines in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Human Vaccines in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Human Vaccines in United States by Downstream Industry
4.2 Demand Volume of Human Vaccines by Downstream Industry in Major Countries
4.2.1 Demand Volume of Human Vaccines by Downstream Industry in New England
4.2.2 Demand Volume of Human Vaccines by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of Human Vaccines by Downstream Industry in The Midwest
4.2.4 Demand Volume of Human Vaccines by Downstream Industry in The West
4.2.5 Demand Volume of Human Vaccines by Downstream Industry in The South
4.2.6 Demand Volume of Human Vaccines by Downstream Industry in Southwest
4.3 Market Forecast of Human Vaccines in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HUMAN VACCINES
5.1 United States Economy Situation and Trend Overview
5.2 Human Vaccines Downstream Industry Situation and Trend Overview
CHAPTER 6 HUMAN VACCINES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of Human Vaccines in United States by Major Players
6.2 Revenue of Human Vaccines in United States by Major Players
6.3 Basic Information of Human Vaccines by Major Players
6.3.1 Headquarters Location and Established Time of Human Vaccines Major Players
6.3.2 Employees and Revenue Level of Human Vaccines Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 HUMAN VACCINES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca
7.1.1 Company profile
7.1.2 Representative Human Vaccines Product
7.1.3 Human Vaccines Sales, Revenue, Price and Gross Margin of AstraZeneca
7.2 Bavarian Nordic
7.2.1 Company profile
7.2.2 Representative Human Vaccines Product
7.2.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bavarian Nordic
7.3 Bharat Biotech
7.3.1 Company profile
7.3.2 Representative Human Vaccines Product
7.3.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bharat Biotech
7.4 CSL Limited
7.4.1 Company profile
7.4.2 Representative Human Vaccines Product
7.4.3 Human Vaccines Sales, Revenue, Price and Gross Margin of CSL Limited
7.5 Emergent BioSolutions, Inc.
7.5.1 Company profile
7.5.2 Representative Human Vaccines Product
7.5.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Emergent BioSolutions, Inc.
7.6 GlaxoSmithKline plc
7.6.1 Company profile
7.6.2 Representative Human Vaccines Product
7.6.3 Human Vaccines Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.7 Johnson & Johnson
7.7.1 Company profile
7.7.2 Representative Human Vaccines Product
7.7.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.8 Merck & Co., Inc.
7.8.1 Company profile
7.8.2 Representative Human Vaccines Product
7.8.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.9 Mymetics
7.9.1 Company profile
7.9.2 Representative Human Vaccines Product
7.9.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Mymetics
7.10 Novartis AG
7.10.1 Company profile
7.10.2 Representative Human Vaccines Product
7.10.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Novartis AG
7.11 Pfizer, Inc.
7.11.1 Company profile
7.11.2 Representative Human Vaccines Product
7.11.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
7.12 Sanofi
7.12.1 Company profile
7.12.2 Representative Human Vaccines Product
7.12.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Sanofi
7.13 Shenzhen Kangtai Biological Products Co., Ltd.
7.13.1 Company profile
7.13.2 Representative Human Vaccines Product
7.13.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Shenzhen Kangtai Biological Products Co., Ltd.
7.14 Takeda Pharmaceutical Company Limited.
7.14.1 Company profile
7.14.2 Representative Human Vaccines Product
7.14.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HUMAN VACCINES
8.1 Industry Chain of Human Vaccines
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HUMAN VACCINES
9.1 Cost Structure Analysis of Human Vaccines
9.2 Raw Materials Cost Analysis of Human Vaccines
9.3 Labor Cost Analysis of Human Vaccines
9.4 Manufacturing Expenses Analysis of Human Vaccines
CHAPTER 10 MARKETING STATUS ANALYSIS OF HUMAN VACCINES
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
